マイオモの適時開示・その他

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     Date of Report (Date of earliest event reported): April 14, 2026

    

MYOMO, INC.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-38109	47-0944526
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

45 Blue Sky Dr. Suite 101
Burlington, Massachusetts		01803
(Address of Principal Executive Offices)		(Zip Code)

     Registrant’s Telephone Number, Including Area Code: 617 996-9058

    

,

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	MYO	NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 14, 2026, upon recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Myomo, Inc. (the "Company"), the Board appointed William J. Febbo to join the Board, effective on April 14, 2026. Mr. Febbo will serve as a Class II director until his term expires at the 2028 annual meeting of shareholders, at which time he will stand for election by the Company’s shareholders. Mr Febbo has not been appointed to serve on any committees of the Board.

Mr. Febbo, 57, currently serves as Chief Executive Officer and Director of Performance Health Systems, a privately-held company that utilizes health and wellness equipment to improve mobility for people at home, businesses, and clinics, which he joined in February 2026. Previously, he served as Chief Executive Officer of OptimizeRx Corporation (NASDAQ: OPRX) from 2015 to 2024. Mr. Febbo has also co-founded and led companies focused on the capital markets, including Merriman Holdings, Inc., and Digital Capital Network. Mr. Febbo holds a BA in International Studies and Spanish from Dickinson College. He is an MIT-affiliated faculty member and mentor in the linQ program, which supports biomedical innovation addressing major health and medical challenges. He also serves as a Mentor for the X & Y Class at Harvard Business School.

In connection with his appointment to the Board, Mr. Febbo was granted 45,000 restricted stock units ("RSUs"), which will vest in their entirety on the first anniversary of the effective date of his appointment to the Board. As a non-employee director, Mr. Febbo will also receive an annual cash retainer of $60,000. In addition, Mr. Febbo will be entitled to receive $85,000 annually, paid in the form of RSUs, which vest over four quarters .Mr. Febbo is not a party to any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K, and there are no arrangements or understandings between Mr. Febbo and any other persons pursuant to which he was selected as a director. In addition, Mr. Febbo has entered into an indemnification agreement with the Company consistent with the form of indemnification agreement entered into between the Company and its existing non-employee directors.

Item 7.01 Regulation FD Disclosure.

On April 16, 2026, the Company issued a press release announcing the appointment of Mr. Febbo. A copy of the Company’s press release relating to this announcement is attached as Exhibit 99.1 to this current report on Form 8-K (the “Report”).

The information contained in Item 7.01 of this Report and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits


Exhibit No.		Description


99.1		Press release issued by Myomo, Inc. on April 16, 2026. furnished herewith.
104		The cover page from the Company’s Form 8-K dated April 16, 2026, formatted in Inline XBRL

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			Myomo, Inc.

Date:	April 16, 2026	By:	/s/ David A. Henry
			David A. Henry Chief Financial Officer

EX-99.1 2 myo-ex99_1.htm EX-99.1 EX-99.1

Exhibit 99.1

Myomo Appoints William J Febbo to its Board of Directors

BURLINGTON, MA. (April 16, 2026) - Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of William “Will” Febbo as a director effective April 14, 2026, to serve until the 2028 annual meeting of stockholders. With this appointment, Myomo has six directors.

Mr. Febbo is an accomplished executive, entrepreneur, and investor with over 30 years of experience in healthcare, financial services, and technology-driven businesses. He has successfully guided organizations through substantial growth, strategic transformations and acquisitions, and significant capital markets initiatives.

“We are pleased to welcome Will to our Board of Directors,” said Paul R. Gudonis, Chairman and Chief Executive Officer of Myomo. "I’m looking forward to Will’s contributions, particularly his expertise in scaling innovative direct-to-patient healthcare solutions which is a key piece of strategy for 2026 and beyond. Additionally, his experience and credibility within capital markets should increase overall awareness of Myomo’s story as a solid investment thesis. "

Mr. Febbo currently serves as Chief Executive Officer and Director of Performance Health Systems, a privately-held company that utilizes health and wellness equipment to improve mobility for people at home, businesses, and clinics, which he joined in February 2026. Previously, he served as Chief Executive Officer of OptimizeRx Corporation (NASDAQ: OPRX) from 2015 to 2024, where he transformed the company from a single point-of-care product provider into an AI-driven omnichannel platform. Under his leadership, revenue grew from $5 million to $92 million, achieving a five-year CAGR of 41%. He also led OptimizeRx's uplisting from OTC to Nasdaq and expanded its digital healthcare network, contributing to significant growth in its market capitalization. Mr. Febbo has also co-founded and led companies focused on the capital markets, including Merriman Holdings, Inc., and Digital Capital Network.

“My interest in Myomo stems from seeing the world adopting robotics within healthcare and looking for platforms which can scale and enable mobility for individuals in need. Myomo is poised to become a market leader in the field of advanced upper extremity orthotics,” said Mr. Febbo. “I look forward to supporting the Company’s continued innovative product development and commercial growth. Focusing on building a platform to unlock additional value as it scales access to its technology for patients with upper extremity weakness or paralysis.”

Mr. Febbo holds a BA in International Studies and Spanish from Dickinson College. He is an MIT-affiliated faculty member and mentor in the linQ program, which supports biomedical innovation addressing major health and medical challenges. He also serves as a Mentor for the X & Y Class at Harvard Business School.

About Myomo

Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. It is currently the only marketed device in the U.S. that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Burlington, Massachusetts, with sales and clinical professionals across the U.S. and representatives internationally.

Myomo Inc. | 45 Blue Sky Dr., Suite 101 | Burlington, MA 01803

TEL: 877.736.9666 www.myomo.com info@myomo.com

For more information, please visit www.myomo.com.

Contacts:

Myomo

ir@myomo.com

Alliance Advisors IR

Tirth T. Patel

tpatel@allianceadvisors.com

212-201-6614

# # #

Myomo Inc. | 45 Blue Sky Dr., Suite 101 | Burlington, MA 01803

TEL: 877.736.9666 www.myomo.com info@myomo.com